Cargando…

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis

BACKGROUND: Coagulopathy has been reported in severely ill patients with coronavirus disease 2019 (COVID‐19). It is unclear whether outpatients with COVID‐19 who are treated with vitamin K antagonists (VKAs) have unstable anticoagulation. OBJECTIVE: To assess the stability of VKA therapy in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camilleri, Eleonora, van Rein, Nienke, van der Meer, Felix J. M., Nierman, Melchior C., Lijfering, Willem M., Cannegieter, Suzanne C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511881/ https://www.ncbi.nlm.nih.gov/pubmed/34667920 http://dx.doi.org/10.1002/rth2.12597

Ejemplares similares

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2022)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists
por: van Heteren, D. Max, et al.
Publicado: (2022)

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists()
por: Visser, Chantal, et al.
Publicado: (2023)

Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
por: Bakker, Sanne, et al.
Publicado: (2022)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda D., et al.
Publicado: (2021)

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial
por: Camilleri, Eleonora, et al.
Publicado: (2023)

Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial
por: Joosten, Linda P T, et al.
Publicado: (2019)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands
por: Chen, Qingui, et al.
Publicado: (2023)

Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
por: Kooiman, Judith, et al.
Publicado: (2014)

Nutrition and venous thrombosis: An exercise in thinking about survivor bias
por: Lijfering, Willem M., et al.
Publicado: (2018)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study
por: Toorop, Myrthe M A, et al.
Publicado: (2021)

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
por: Jacobs, M. S., et al.
Publicado: (2019)

Current and future burden of venous thrombosis: Not simply predictable
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis
por: Boer, Cindy G, et al.
Publicado: (2021)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
por: Fanaroff, Alexander C, et al.
Publicado: (2022)

Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants
por: Brinkmeier-Theofanopoulou, Maria, et al.
Publicado: (2018)

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants
por: Darche, Fabrice F., et al.
Publicado: (2023)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
por: Malagù, Michele, et al.
Publicado: (2023)

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
por: Shiyovich, Arthur, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
por: Yang, Hayang, et al.
Publicado: (2019)

Pocket hematoma after pacemaker or defibrillator surgery: Direct oral anticoagulants versus vitamin K antagonists
por: de Heide, John, et al.
Publicado: (2022)

Comparative Risk of Bleeding of Anticoagulant Therapy with Vitamin K Antagonists (VKAs) and with Non-Vitamin K Antagonists in Patients Undergoing Dental Surgery
por: Manfredini, Mattia, et al.
Publicado: (2021)

Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aa23o6tk9563g1jqjl1t41r8om